Scarica l'app Stockscreener
143.26
8.07%
10.70
Dopo l'orario di chiusura:
143.43
0.17
+0.12%
Grail Inc Borsa (GRAL) Ultime notizie
A Cancer Test Has Investors Betting Big. But Will Insurers Pay? - WSJ
The Galleri MCD vote: What FDA asked its advisors to ignore - The Cancer Letter
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run. - Yahoo Finance
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail' - Investor's Business Daily
Is GRAIL (GRAL) Expensive Following PATHFINDER 2 Results And The FDA Panel Vote? - Simply Wall Street
GRAL Stock Rockets Higher As Traders Hunt Momentum - StocksToTrade
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL) - Seeking Alpha
Grail's stock jumps 55% after positive FDA advi... - Pluang
Grail stock price target raised to $150 by Canaccord on FDA outlook - Investing.com
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test - Oncology Nursing News
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 By Investing.com - Investing.com South Africa
Form 4 Grail Inc For: 26 September By Investing.com - Investing.com Australia
Grail CFO Aaron Freidin sells $382,679 in company stock By Investing.com - Investing.com South Africa
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 - Investing.com
FDA Advisory Panel Backs Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test - clpmag.com
Just a Flesh Wound: The Combative Quest for Cancer’s Holy Grail - Inside Precision Medicine
FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote - qz.com
FDA panel endorses Grail Galleri multi-cancer blood test - Yahoo
Mizuho raises Grail stock price target to $100 on FDA panel vote - Investing.com Canada
Mizuho raises Grail stock price target to $100 on FDA panel vote By Investing.com - Investing.com South Africa
Here's Why Grail Stock Surged 55% This Week - The Motley Fool
Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL) - theglobeandmail.com
GRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focus - Stocktwits
Grail multicancer detection test wins FDA advisers’ backing - BioPharma Dive
This Controversial Cancer Test Just Passed a Key FDA Vote. Here's Why It's Dividing Experts - inc.com
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued? - Yahoo Finance
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test - Investor's Business Daily
FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says - FOX 10 Phoenix
GRAL Stock Surges As Traders Target High-Momentum Breakout - timothysykes.com
GRAL Stock Rockets As Traders Chase Breakout Momentum - StocksToTrade
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool - Benzinga
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test - marketscreener.com
One blood test could screen you for 50 cancers. Here’s why it’s controversial. - The Washington Post
Grail stock hits all-time high at 119.09 USD - Investing.com
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply. - Barron's
Grail stock hits all-time high at 119.09 USD By Investing.com - Investing.com Canada
Canaccord reiterates Buy on Grail stock after FDA panel vote - Investing.com
GRAIL Surges As FDA Panel Backs Cancer Blood Test - TipRanks
What is next for Grail stock after surging on positive FDA comments? - Investing.com
FDA panel endorses first-of-a-kind cancer blood test from Grail - Daily Herald
Grail survives adcomm vote as it awaits FDA decision for cancer blood test - Fierce Biotech
FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test - allsci.com
Canaccord reiterates Buy on Grail stock after FDA panel vote By Investing.com - Investing.com Nigeria
Grail MCED Test is Safe, Effective, Experts Tell FDA, While Questioning ‘Early Detection’ Claim - GenomeWeb
FDA panel endorses GRAIL’s multi-cancer early detection test - yahoo.com
Premarket movers: Stitch Fix tumbles, Grail surges - Investing.com
Why is Grail stock surging today? - Investing.com
FDA panel backs Galleri blood test that screens for more than 50 cancers - Straight Arrow
FDA panel endorses blood cancer test from Grail - Boston 25 News
New blood test can detect more than 50 types of cancer. Here’s what to know - WEAU
FDA Panel Backs GRAIL’s Multi-Cancer Test, But Split Votes Put ‘Early Detection’ Claim In Play - insights.citeline.com
FDA advisory panel endorses Grail blood test for cancer, saying benefits outweigh risks - STAT
Grail's cancer blood test faces high-stakes FDA review - Bedford Gazette
Grail cancer test gets lukewarm backing from FDA adcomm - pharmaphorum
Why Is Grail (NASDAQ:GRAL) Moving Into Focus? - Kalkine Media
How Investors May Respond To GRAIL (GRAL) Favorable FDA Panel Vote - simplywall.st
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):